TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE
| Autor: | Jennifer N. Langan, Chen Gilor, James G. Johnson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Blood Glucose
Male Glycosuria endocrine system medicine.medical_specialty Leontopithecus endocrine system diseases 040301 veterinary sciences 030209 endocrinology & metabolism 0403 veterinary science 03 medical and health sciences 0302 clinical medicine biology.animal Internal medicine Diabetes mellitus Diabetes Mellitus medicine Animals Hypoglycemic Agents Lion tamarin Leontopithecus rosalia General Veterinary biology Venoms business.industry Monkey Diseases nutritional and metabolic diseases 04 agricultural and veterinary sciences General Medicine biology.organism_classification medicine.disease Glucagon-like peptide-1 Metformin Endocrinology Delayed-Action Preparations Exenatide Animals Zoo Animal Science and Zoology medicine.symptom Peptides business medicine.drug Glipizide |
| Zdroj: | Journal of Zoo and Wildlife Medicine. 47:903-906 |
| ISSN: | 1937-2825 1042-7260 |
| Popis: | An 8-yr-old male golden lion tamarin ( Leontopithecus rosalia ) was diagnosed with diabetes mellitus based on hyperglycemia and persistent glycosuria. Initial treatment consisted of the oral antihyperglycemic medications glipizide and metformin that resulted in decreased blood glucose concentrations; however, marked glycosuria persisted. Insufficient improvement on oral antihyperglycemic therapy and poor feasibility of daily subcutaneous insulin therapy led to an investigation into an alternative therapy with extended-release exenatide, a glucagon-like peptide-1 (GLP-1) mimetic, at a dosage of 0.13 mg/kg subcutaneously once per month. Following treatment with exenatide, the persistent glycosuria resolved, the animal maintained normal blood glucose concentrations, and had lower serum fructosamine concentrations compared to pretreatment levels. Based on these findings, extended-release exenatide could be considered as a therapeutic option in nonhuman primates with diabetes mellitus that do not respond to oral antihyperglycemics and in which daily subcutaneous insulin is not feasible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|